Close Menu

NEW YORK – Myriad Genetics submitted a supplemental premarket approval application with the US Food and Drug Administration for myChoice CDx to assess newly diagnosed advanced ovarian cancer patients with homologous recombination deficiency (HRD), who are likely to respond to niraparib (GlaxoSmithKline's Zejula).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.